TITLE

INVESTMENT BANKING DATABASE: HEATHCARE

PUB. DATE
June 2003
SOURCE
Investment Dealers' Digest;6/30/2003, Vol. 69 Issue 26, p40
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Presents statistics on healthcare companies involved in investment banking worldwide as of June 23, 2003. Top U.S. new issues bookrunners as of June 23, 2003; Stock price of Life Tec Group; Global debt deal of Johnson & Johnson Inc.; Loan description of Watson Pharmaceuticals Inc.
ACCESSION #
10202345

 

Related Articles

  • J&J plan: If you can't beat generics, join 'em. Kaltwasser, Jared // njbiz;11/8/2010, Vol. 23 Issue 45, p2 

    The article reports on the plan of Johnson & Johnson to partner with Watson Pharmaceuticals in order to market an authorized version of Concerta treatment for attention deficit hyperactivity disorder (ADHD).

  • Update.  // Medical Marketing & Media;Jan2004, Vol. 39 Issue 1, p9 

    Reports on developments involving companies in the pharmaceutical industry in the U.S. Reason for the subpoena received by Johnson & Johnson Inc. and Watson Pharmaceuticals Inc; Business division formed by IntraMed Educational Group; Changes made by Schering-Plough Corp. into its payroll scheme.

  • The Industry.  // Pharmaceutical Representative;May2006, Vol. 36 Issue 5, p10 

    The article offers developments in the pharmaceutical industry. Watson Pharmaceuticals Inc. reveals their definitive agreement of acquiring Plantation, Florida-based Andrx Corp., which will make them the 3rd largest generic drug maker in the U.S. AstraZeneca PLC had ceased its fee-for-service...

  • Watson will market OTC drug products.  // Drug Store News;5/20/96, Vol. 18 Issue 8, p101 

    Reports that Watson Pharmaceuticals has formed a division to develop, manufacture and market a portfolio of over-the-counter drug products. Officers of the division; Expansion strategies.

  • Transforming to conquer tomorrow.  // Drug Store News;2/16/98, Vol. 20 Issue 3, pCP16 

    Profiles Corona, California-based Watson Pharmaceuticals Inc. Comment by Allen Chao, chairman and chief executive officer of Watson Pharmaceuticals Inc.; Trends affecting the generic drug industry in the United States; Expansion plans by the company for 1998.

  • Soc Gen Funds Pharmaceutical Deal. Phadungchai, Naruth // Bank Loan Report;07/24/2000, Vol. 15 Issue 30, p3 

    Reports the launching of a credit facility for Watson Pharmaceuticals Inc. Worth of the deal; Price structure; Credit rating.

  • Watson creates OTC division. Snyder, Karyn // Drug Topics;5/6/96, Vol. 140 Issue 9, p33 

    Reports that Watson Pharmaceuticals Inc. has formed an over-the-counter (OTC) division. Capability of the company in the OTC market, according to chief executive officer Allan Chao; Appointment of Lynne Millheiser as head of the division.

  • Sicor Sticks to Niche as Watson Boosts Branded. Reed, Vita // Orange County Business Journal;4/8/2002, Vol. 25 Issue 14, p1 

    Focuses on the business strategies of two pharmaceutical companies in the U.S. Approval received by Sicor Inc. for an injectable drug to fight calcification; Decision of Watson Pharmaceuticals Inc. to lower earnings projections for the fourth quarter of 2002; Business plans of the two companies.

  • Topical gel for treatment ofOAB.  // Clinical Advisor;Jul2009, Vol. 12 Issue 7, p19 

    The article evaluates the Gelnique, an antipasmodic/anticholinergic gel from Watson.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics